Seminars in Diagnostic Pathology
Volume 27, Issue 1 , Pages 69-76 , February 2010

Neuroendocrine differentiation in breast cancer: established facts and unresolved problems

  • Luisella Righi, MD, PhD

      Affiliations

    • Department of Clinical and Biological Sciences, University of Turin at San Luigi Hospital, Orbassano, Torino, Italy
    • ,
  • Anna Sapino, MD

      Affiliations

    • Department of Biomedical Sciences and Human Oncology, University of Turin, Torino, Italy
    • ,
  • Caterina Marchiò, MD, PhD

      Affiliations

    • Department of Biomedical Sciences and Human Oncology, University of Turin, Torino, Italy
    • ,
  • Mauro Papotti, MD

      Affiliations

    • Department of Clinical and Biological Sciences, University of Turin at San Luigi Hospital, Orbassano, Torino, Italy
    • ,
  • Gianni Bussolati, MD, FRCPath

      Affiliations

    • Department of Biomedical Sciences and Human Oncology, University of Turin, Torino, Italy
    • Corresponding Author InformationAddress reprint requests and correspondence: Gianni Bussolati, MD, FRCPath, Department of Biomedical Sciences and Human Oncology, University of Turin, Via Santena, 7, 10126 Torino, Italy

References 

  1. Cubilla AL, Woodruff JM. Primary carcinoid tumor of the breast (A report of eight patients). Am J Surg Pathol. 1977;1:283–292
  2. Cross AS, Azzopardi JG, Krausz T, et al. A morphological and immunocytochemical study of a distinctive variant of ductal carcinoma in-situ of the breast. Histopathology. 1985;9:21–37
  3. Sapino A, Righi L, Cassoni P, et al. Expression of the neuroendocrine phenotype in carcinomas of the breast. Semin Diagn Pathol. 2000;17:127–137
  4. Bussolati G, Gugliotta P, Sapino A, et al. Chromogranin-reactive endocrine cells in argyrophilic carcinomas (“carcinoids”) and normal tissue of the breast. Am J Pathol. 1985;120:186–192
  5. Pagani A, Papotti M, Hofler H, et al. Chromogranin A and B gene expression in carcinomas of the breast (Correlation of immunocytochemical, immunoblot, and hybridization analyses). Am J Pathol. 1990;136:319–327
  6. Ellis P, Schnitt SJ, Sastre-Garau X. Invasive breast carcinoma. In:  Tavassoli FA,  Devilee P editor. Tumours of the Breast and Female Genital Organs: Pathology and Genetics. Lyon, France: IARC Press; 2003;
  7. Maluf HM, Koerner FC. Carcinomas of the breast with endocrine differentiation: A review. Virchows Arch. 1994;425:449–457
  8. Hull MT, Warfel KA. Mucinous breast carcinomas with abundant intracytoplasmic mucin and neuroendocrine features: Light microscopic, immunohistochemical, and ultrastructural study. Ultrastruct Pathol. 1987;11:29–38
  9. Papotti M, Tanda F, Bussolati G, et al. Argyrophilic neuroendocrine carcinoma of the male breast. Ultrastruct Pathol. 1993;17:115–121
  10. Taxy JB, Tischler AS, Insalaco SJ, et al. “Carcinoid” tumor of the breast (A variant of conventional breast cancer?). Hum Pathol. 1981;12:170–179
  11. Fisher ER, Palekar AS. Solid and mucinous varieties of so-called mammary carcinoid tumors. Am J Clin Pathol. 1979;72:909–916
  12. Papotti M, Macri L, Finzi G, et al. Neuroendocrine differentiation in carcinomas of the breast: A study of 51 cases. Semin Diagn Pathol. 1989;6:174–188
  13. Capella C, Eusebi V, Mann B, et al. Endocrine differentiation in mucoid carcinoma of the breast. Histopathology. 1980;4:613–630
  14. Lopez-Bonet E, Alonso-Ruano M, Barraza G, et al. Solid neuroendocrine breast carcinomas: Incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep. 2008;20:1369–1374
  15. Volante M, Righi L, Asioli S, et al. Goblet cell carcinoids and other mixed neuroendocrine/nonneuroendocrine neoplasms. Virchows Arch. 2007;451(suppl 1):S61–S69
  16. Sapino A, Righi L, Cassoni P, et al. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. Mod Pathol. 2001;14:768–776
  17. Papotti M, Gherardi G, Eusebi V, et al. Primary oat cell (neuroendocrine) carcinoma of the breast (Report of four cases). Virchows Arch A Pathol Anat Histopathol. 1992;420:103–108
  18. Adegbola T, Connolly CE, Mortimer G. Small cell neuroendocrine carcinoma of the breast: A report of three cases and review of the literature. J Clin Pathol. 2005;58:775–778
  19. Ersahin C, Bandyopadhyay S, Bhargava R. Thyroid transcription factor-1 and “basal marker”—Expressing small cell carcinoma of the breast. Int J Surg Pathol. 2009;17:368–372
  20. Shin SJ, DeLellis RA, Rosen PP. Small cell carcinoma of the breast—Additional immunohistochemical studies. Am J Surg Pathol. 2001;25:831–832
  21. Moriya T, Kanomata N, Kozuka Y, et al. Usefulness of immunohistochemistry for differential diagnosis between benign and malignant breast lesions. Breast Cancer. 2009;16:173–178
  22. Capella C, Usellini L, Papotti M, et al. Ultrastructural features of neuroendocrine differentiated carcinomas of the breast. Ultrastruct Pathol. 1990;14:321–334
  23. Makretsov N, Gilks CB, Coldman AJ, et al. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol. 2003;34:1001–1008
  24. Kiriakogiani-Psaropoulou P, Malamou-Mitsi V, Martinopoulou U, et al. The value of neuroendocrine markers in non-small cell lung cancer: A comparative immunohistopathologic study. Lung Cancer. 1994;11:353–364
  25. Papotti M, Sapino A, Righi L, et al. 34betaE12 cytokeratin immunodetection in the differential diagnosis of neuroendocrine carcinomas of the breast. Appl Immunohistochem Mol Morphol. 2001;9:229–233
  26. Tse GM, Tan PH, Lau KM, et al. Breast cancer in the elderly: A histological assessment. Histopathology. 2009;55:441–451
  27. Haagensen DE, Mazoujian G, Dilley WG, et al. Breast gross cystic disease fluid analysis. I (Isolation and radioimmunoassay for a major component protein). J Natl Cancer Inst. 1979;62:239–247
  28. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer. 1999;6:503–519
  29. Papotti M, Macri L, Bussolati G, et al. Correlative study on neuro-endocrine differentiation and presence of somatostatin receptors in breast carcinomas. Int J Cancer. 1989;43:365–369
  30. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389–427
  31. Bootsma AH, van Eijck C, Schouten KK, et al. Somatostatin receptor-positive primary breast tumors: Genetic, patient and tumor characteristics. Int J Cancer. 1993;54:357–362
  32. Korner M, Eltschinger V, Waser B, et al. Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: Lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography. Am J Surg Pathol. 2005;29:1642–1651
  33. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med. 2005;46(suppl 1):67S–75S
  34. Panareo S, Carcoforo P, Lanzara S, et al. Radiolabelled somatostatin analogs for diagnosis and radio-guided surgery of neuroendocrine breast cancer undetectable with conventional imaging procedures. Breast. 2008;17:111–114
  35. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752
  36. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression datasets. Proc Natl Acad Sci U S A. 2003;100:8418–8423
  37. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96
  38. Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;216:141–150
  39. Weigelt B, Geyer FC, Horlings HM, et al. Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod Pathol. 2009;22:1401–1414
  40. Sapino A, Papotti M, Pietribiasi F, et al. Diagnostic cytological features of neuroendocrine differentiated carcinoma of the breast. Virchows Arch. 1998;433:217–222
  41. Tang W, Taniguchi E, Wang X, et al. Loss of cell cohesion in breast cytology as a characteristic of neuroendocrine carcinoma. Acta Cytol. 2002;46:835–840
  42. Ng WK, Poon CS, Kong JH. Fine needle aspiration cytology of ductal breast carcinoma with neuroendocrine differentiation (Review of eight cases with histologic correlation). Acta Cytol. 2002;46:325–331
  43. Rovera F, Masciocchi P, Coglitore A, et al. Neuroendocrine carcinomas of the breast. Int J Surg. 2008;6(suppl 1):S113–S115
  44. Berruti A, Saini A, Leonardo E, et al. Management of neuroendocrine differentiated breast carcinoma. Breast. 2004;13:527–529
  45. Tse GM, Ma TK, Chu WC, et al. Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters. Mod Pathol. 2004;17:568–572
  46. Sapino A, Papotti M, Righi L, et al. Clinical significance of neuroendocrine carcinoma of the breast. Ann Oncol. 2001;12(suppl 2):S115–S117
  47. van Krimpen C, Elferink A, Broodman CA, et al. The prognostic influence of neuroendocrine differentiation in breast cancer: Results of a long-term follow-up study. Breast. 2004;13:329–333
  48. Miremadi A, Pinder SE, Lee AH, et al. Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology. 2002;40:215–222
  49. Berruti A, Mosca A, Porpiglia F, et al. Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease. J Urol. 2007;178:838–843
  50. Tsang WY, Chan JK. Endocrine ductal carcinoma in situ (E-DCIS) of the breast: A form of low-grade DCIS with distinctive clinicopathologic and biologic characteristics. Am J Surg Pathol. 1996;20:921–943
  51. Satake T, Matsuyama M. Endocrine cells in a normal breast and non-cancerous breast lesion. Acta Pathol Jpn. 1991;41:874–878
  52. Fetissof F, Dubois MP, Arbeille-Brassart B, et al. Argyrophilic cells in mammary carcinoma. Hum Pathol. 1983;14:127–134
  53. Kawasaki T, Nakamura S, Sakamoto G, et al. Neuroendocrine ductal carcinoma in situ (NE-DCIS) of the breast—Comparative clinicopathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases. Histopathology. 2008;53:288–298
  54. Rindi G, Buffa R, Sessa F, et al. Chromogranin A, B and C immunoreactivities of mammalian endocrine cells (Distribution, distinction from costored hormones/prohormones and relationship with the argyrophil component of secretory granules). Histochemistry. 1986;85:19–28
  55. Rossi S, Laurino L, Furlanetto A, et al. Rabbit monoclonal antibodies: A comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Clin Pathol. 2005;124:295–302
  56. Iyoda A, Hiroshima K, Toyozaki T, et al. Clinical characterization of pulmonary large cell neuroendocrine carcinoma and large cell carcinoma with neuroendocrine morphology. Cancer. 2001;91:1992–2000
  57. Giovanella L, Marelli M, Ceriani L, et al. Evaluation of chromogranin A expression in serum and tissues of breast cancer patients. Int J Biol Markers. 2001;16:268–272

 This work was supported by Regione Piemonte Ricerca Sanitaria Finalizzata, Compagnia San Paolo, Fondazione Cassa di Risparmio di Cuneo.

PII: S0740-2570(09)00093-8

doi: 10.1053/j.semdp.2009.12.003

Seminars in Diagnostic Pathology
Volume 27, Issue 1 , Pages 69-76 , February 2010

Article Tools

* Image Usage & Resolution